Ubat Darah Tinggi
sebabkan kanser
HSA recalls
three brands of high blood pressure drug losartan over cancer risk
Published
Mar 28, 2019, 6:38 pm
SINGAPORE
- Three brands of a medicine prescribed for high blood pressure are being
recalled because they contain higher than acceptable amounts of nitrosamine
impurity, which can potentially cause cancer.
However,
patients currently taking these three brands of losartan are advised not to
stop taking the medicine, as the immediate health risk is low, the Health
Sciences Authority said in a statement on Thursday (March 28).
The
drugs affected are the 50mg and 100mg tablets from these brands: Hypergen,
Losagen and Losartas.
The
Ministry of Health (MOH) said that about 137,000 patients in Singapore are
using the three recalled brands of losartan.
Of
these, about 130,000 patients have been prescribed Losartas at public hospitals
and polyclinics.
With
supplies of the safe varieties of losartan expected to be affected by the
recall, the MOH has advised doctors to prescribe the medication on a one-month
basis so that all patients have enough medicine to control their high blood
pressure.
It
said: "This ensures that patients in all settings are able to promptly
receive the medication they need. This may be the practice for the next six
months."
It
added that patients whose next appointment is before July 1 should wait until
then to speak to their doctor, who will advise them on suitable alternative
medicines. Those who have appointments after July 1 "will be contacted for
an earlier consultation and/or medication review".
The
HSA said these tablets contain a losartan ingredient made by Indian
pharmaceutical company Hetero Labs that showed trace amounts of the impurity.
According
to the Food and Drug Administration of the United States, the company has
been recalling certain batches of these medicines since last month.
The
HSA said that several losartan drugs have also been recalled in other countries
in recent weeks.
It
decided to test all losartan products here and identified that three of the 10
brands on sale here were affected.
It
has also tested other drugs within the same class of hypertensive medication,
such as valsartan, which has been recalled in some foreign markets. They were
found to be safe.
The
statement added: "HSA will require companies to make the necessary changes
to their manufacturing process to ensure that the medicines do not contain
these impurities in future."
The
MOH said: "The public healthcare sector has made additional orders of unaffected
brands of losartan.
"The
additional supplies will arrive progressively from a few weeks' time. Importers
will also be setting aside additional supplies for private healthcare
providers."
Public
sector patients will be refunded if they returned the affected medicine.
Replacement medicines "during the interim period" will be charged at
the same or lower price.
The
MOH added: "Charges incurred for services such as additional consultations
or tests to assess suitability for a switch in medicine will also be
waived."
.
..
No comments:
Post a Comment
Note: only a member of this blog may post a comment.